(Q24799492)

3 July 2017

title

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study (English)

1 reference

3 July 2017

1 reference

Ming-Lung Yu

1

1 reference

3 July 2017

Chia-Yen Dai

2

1 reference

3 July 2017

Shinn-Cherng Chen

3

1 reference

3 July 2017

Li-Po Lee

4

1 reference

3 July 2017

Ming-Yen Hsieh

5

1 reference

3 July 2017

Zu-Yau Lin

6

1 reference

3 July 2017

Ming-Yuh Hsieh

7

1 reference

3 July 2017

Liang-Yen Wang

8

1 reference

3 July 2017

Jung-Fa Tsai

9

1 reference

3 July 2017

Wen-Yu Chang

10

1 reference

3 July 2017

Wan-Long Chuang

11

1 reference

3 July 2017

language of work or name

English

0 references

publication date

12 April 2005

1 reference

3 July 2017

published in

BMC Infectious Diseases

1 reference

3 July 2017

volume

5

1 reference

3 July 2017

issue

1

0 references

page(s)

27

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

3 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Hepatitis C virus infection

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Therapy of hepatitis C: overview

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-27

Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-27

Principles of interferon induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-27

Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-27

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-27

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-27

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-27

Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1090579

EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement

28 November 2018

1 reference

12 December 2020

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

12 December 2020

Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C

1 reference

12 December 2020

A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C

1 reference

12 December 2020

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

12 December 2020

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2334-5-27

1 reference

Dimensions Publication ID

3 July 2017

1010775120

0 references

Fatcat ID

release_gnyujogu2vgdjfytrtc3s5r3dq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gnyujogu2vgdjfytrtc3s5r3dq

24 November 2022

mapped directly with Wikidata item

PMC publication ID

1090579

0 references

1 reference